Literature DB >> 20223820

Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.

Aymone Gurtner1, Giuseppe Starace, Giuseppe Norelli, Giulia Piaggio, Ada Sacchi, Gianluca Bossi.   

Abstract

Mitogen-activated protein kinase kinase 3 (MAP2K3) is a member of the dual specificity kinase group. Growing evidence links MAP2K3 to invasion and tumor progression. Here, we identify MAP2K3 as a transcriptional target of endogenous gain-of-function p53 mutants R273H, R175H, and R280K. We show that MAP2K3 modulation occurred at the mRNA and protein levels and that endogenous mutant p53 proteins are capable of binding to and activate the MAP2K3 promoter. In addition, we found that the studied p53 mutants regulate MAP2K3 gene expression through the involvement of the transcriptional cofactors NF-Y and NF-kappaB. Finally, functional studies showed that endogenous MAP2K3 knockdown inhibits proliferation and survival of human tumor cells, whereas the ectopic expression of MAP2K3 can rescue the proliferative defect induced by mutant p53 knockdown. Taken together, our findings define a novel player through which mutant p53 exerts its gain-of-function activity in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20223820      PMCID: PMC2863202          DOI: 10.1074/jbc.M109.094813

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

Authors:  J Sampath; D Sun; V J Kidd; J Grenet; A Gandhi; L H Shapiro; Q Wang; G P Zambetti; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

3.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

4.  Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference.

Authors:  Maciej Wiznerowicz; Didier Trono
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  ONCOMINE: a cancer microarray database and integrated data-mining platform.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

Review 6.  Rescuing the function of mutant p53.

Authors:  A N Bullock; A R Fersht
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

7.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.

Authors:  D A Notterman; U Alon; A J Sierk; A J Levine
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

8.  Modulation of gene expression by tumor-derived p53 mutants.

Authors:  Mariano J Scian; Katherine E R Stagliano; Michelle A Ellis; Sajida Hassan; Melissa Bowman; Michael F Miles; Swati Palit Deb; Sumitra Deb
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

9.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

10.  Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.

Authors:  Amir Zalcenstein; Perry Stambolsky; Lilach Weisz; Martina Müller; David Wallach; Tanya M Goncharov; Peter H Krammer; Varda Rotter; Moshe Oren
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

View more
  46 in total

1.  Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity.

Authors:  Timo Quante; Benjamin Otto; Marie Brázdová; Iva Kejnovská; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Cell Cycle       Date:  2012-08-21       Impact factor: 4.534

2.  Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin.

Authors:  Barbara Tanno; Fabiola Sesti; Vincenzo Cesi; Gianluca Bossi; Giovanna Ferrari-Amorotti; Rita Bussolari; Donatella Tirindelli; Bruno Calabretta; Giuseppe Raschellà
Journal:  J Biol Chem       Date:  2010-07-11       Impact factor: 5.157

Review 3.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

4.  Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies.

Authors:  Gabriella D'Orazi; Marco Cordani; Mara Cirone
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

5.  Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.

Authors:  Xiangbing Meng; Laura L Laidler; Elizabeth A Kosmacek; Shujie Yang; Zhi Xiong; Danlin Zhu; Xinjun Wang; Donghai Dai; Yuping Zhang; Xiaofang Wang; Pavla Brachova; Lina Albitar; Dawei Liu; Fiorenza Ianzini; Michael A Mackey; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2012-11-09       Impact factor: 5.482

6.  YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.

Authors:  Silvia Di Agostino; Giovanni Sorrentino; Eleonora Ingallina; Fabio Valenti; Maria Ferraiuolo; Silvio Bicciato; Silvano Piazza; Sabrina Strano; Giannino Del Sal; Giovanni Blandino
Journal:  EMBO Rep       Date:  2015-12-21       Impact factor: 8.807

Review 7.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

8.  Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cells.

Authors:  Inamul Haque; Snigdha Banerjee; Smita Mehta; Archana De; Monami Majumder; Matthew S Mayo; Suman Kambhampati; Donald R Campbell; Sushanta K Banerjee
Journal:  J Biol Chem       Date:  2011-10-21       Impact factor: 5.157

9.  Augmentation of the cytotoxic effects of zinc oxide nanoparticles by MTCP conjugation: Non-canonical apoptosis and autophagy induction in human adenocarcinoma breast cancer cell lines.

Authors:  Najmeh Mozdoori; Shahrokh Safarian; Nader Sheibani
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2017-04-26       Impact factor: 7.328

10.  Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.

Authors:  F Garibaldi; E Falcone; D Trisciuoglio; T Colombo; K Lisek; D Walerych; G Del Sal; P Paci; G Bossi; G Piaggio; A Gurtner
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.